Gary Barnette - Veru Chief Officer
| VERU Stock | USD 0.58 0.03 4.92% |
Insider
Gary Barnette is Chief Officer of Veru Inc
| Age | 57 |
| Address | 2916 North Miami Avenue, Miami, FL, United States, 33127 |
| Phone | 305 509 6897 |
| Web | https://verupharma.com |
Veru Management Efficiency
The company has return on total asset (ROA) of (0.6436) % which means that it has lost $0.6436 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2672) %, meaning that it created substantial loss on money invested by shareholders. Veru's management efficiency ratios could be used to measure how well Veru manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.77 in 2025. Return On Capital Employed is likely to gain to -0.65 in 2025. At this time, Veru's Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 19.6 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 7 M in 2025.Similar Executives
| Showing other executives | INSIDER Age | ||
| John III | Novavax | 58 | |
| Kathleen Wilkinson | 2Seventy Bio | 52 | |
| Susan AbuAbsi | 2Seventy Bio | N/A | |
| Walter MD | Anavex Life Sciences | N/A | |
| Robert MD | Lexicon Pharmaceuticals | 80 | |
| Michael Hoffman | Annovis Bio | 69 | |
| William Ciambrone | Sarepta Therapeutics | 60 | |
| Dr RPh | Anavex Life Sciences | N/A | |
| MD MPH | Anavex Life Sciences | N/A | |
| Jeffrey Ludwig | Puma Biotechnology | 59 | |
| Igor Bilinsky | Iovance Biotherapeutics | 52 | |
| Kevin PharmD | Axsome Therapeutics | 46 | |
| David MBA | Seres Therapeutics | 63 | |
| Esq JD | Iovance Biotherapeutics | 48 | |
| Louise RodinoKlapac | Sarepta Therapeutics | 47 | |
| JeanMarc MBA | Iovance Biotherapeutics | 53 | |
| MBA MS | Anavex Life Sciences | 56 | |
| Friedrich MD | Iovance Biotherapeutics | 58 | |
| Howard MBA | Iovance Biotherapeutics | 65 | |
| Gale Smith | Novavax | 74 | |
| Mike Kelly | Lexicon Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -1.27 | ||||
| Return On Asset | -0.64 |
Veru Inc Leadership Team
Elected by the shareholders, the Veru's board of directors comprises two types of representatives: Veru inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Veru. The board's role is to monitor Veru's management team and ensure that shareholders' interests are well served. Veru's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Veru's outside directors are responsible for providing unbiased perspectives on the board's policies.
| MB LLB, Executive Sales | ||
| Gary Barnette, Chief Officer | ||
| Gary Bird, Executive Affairs | ||
| Jason Davies, Europe, UK | ||
| Michele CPA, CFO Officer | ||
| Philip JD, Executive Counsel | ||
| FACS FACS, Pres Chairman | ||
| Martin Tayler, Executive Operations | ||
| MD MBA, Chief Officer | ||
| Samuel Fisch, Executive Communications | ||
| Domingo MD, Executive Operations | ||
| Michael JD, General VP | ||
| MD FACS, President Chairman | ||
| Michele Greco, CFO Officer | ||
| JD CPA, Executive Development | ||
| Joel Batten, Ex Franchise | ||
| Michael Purvis, General VP |
Veru Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Veru a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.27 | ||||
| Return On Asset | -0.64 | ||||
| Profit Margin | (2.65) % | ||||
| Operating Margin | (2.79) % | ||||
| Current Valuation | 73.92 M | ||||
| Shares Outstanding | 146.38 M | ||||
| Shares Owned By Insiders | 14.10 % | ||||
| Shares Owned By Institutions | 42.03 % | ||||
| Number Of Shares Shorted | 12.79 M | ||||
| Price To Earning | 240.00 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Veru Stock Analysis
When running Veru's price analysis, check to measure Veru's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veru is operating at the current time. Most of Veru's value examination focuses on studying past and present price action to predict the probability of Veru's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veru's price. Additionally, you may evaluate how the addition of Veru to your portfolios can decrease your overall portfolio volatility.